How China’s National Reimbursement Decisions Affect Clinical Development
How China’s National Reimbursement Decisions Affect Clinical Development The Influence of China’s National Reimbursement on Clinical Development Introduction China’s National Reimbursement Drug List (NRDL) has become one of the most influential policy levers shaping clinical development strategies. Inclusion on the NRDL determines whether a drug is reimbursed under China’s basic medical insurance system, significantly affecting…
Read More “How China’s National Reimbursement Decisions Affect Clinical Development” »